.gif)
Indian Immunologicals Ltd (IIL), a leading biological company inaugurated its new bovine serum manufacturing facility in New Zealand.
Pristine Biologicals (NZ) Ltd (PBL), a wholly owned subsidiary of IIL, was inaugurated by National Dairy Development Board (NDDB) chairman T. Nanda Kumar, in the presence of New Zealander's Food Safety Development and Primary Industries Minister Jo Goodhew, IIL MD and PBL director K. V. Balasubramaniam, said a statement by IIL here.
IIL established PBL last year to gain control over the supplies of a key ingredient used in vaccine manufacture. Serum from New Zealand is highly regarded as the country is free from several diseases listed by the World Organisation for Animal Health (OIE). The new plant can manufacture up to 300 tonne of serum.
"Pristine would bring the science of biopharmaceuticals to the users of bovine serum and the rigor in quality assurance and management which will in turn ensure that users bring high quality to their products," said Balasubramaniam.
"With this new facility IIL not only becomes self sufficient for a key ingredient but also has spare capacity to provide it to other quality conscious manufacturers as well," said IIL's deputy managing director Anand Kumar. IANS
Subscribe to PharmaTutor News Alerts by Email >>
